Cencora, Inc. (NYSE:COR) Shares Acquired by Trajan Wealth LLC

Trajan Wealth LLC boosted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 5.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 112,446 shares of the company's stock after purchasing an additional 5,885 shares during the period. Cencora makes up approximately 1.4% of Trajan Wealth LLC's holdings, making the stock its 16th largest position. Trajan Wealth LLC owned about 0.06% of Cencora worth $25,264,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. MML Investors Services LLC increased its position in Cencora by 2.8% during the fourth quarter. MML Investors Services LLC now owns 87,852 shares of the company's stock valued at $19,739,000 after acquiring an additional 2,402 shares during the last quarter. MetLife Investment Management LLC lifted its stake in shares of Cencora by 1.5% in the 4th quarter. MetLife Investment Management LLC now owns 53,573 shares of the company's stock worth $12,037,000 after purchasing an additional 798 shares during the period. Norinchukin Bank The boosted its holdings in shares of Cencora by 10.1% in the fourth quarter. Norinchukin Bank The now owns 7,970 shares of the company's stock worth $1,791,000 after buying an additional 733 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Cencora during the fourth quarter valued at approximately $1,652,000. Finally, Dimensional Fund Advisors LP increased its holdings in Cencora by 5.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,511,004 shares of the company's stock valued at $339,494,000 after buying an additional 78,759 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

COR has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research note on Tuesday, April 15th. Finally, Bank of America increased their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $284.55.

Cencora Trading Down 1.0 %

COR traded down $2.82 during trading on Thursday, reaching $281.89. The company had a trading volume of 1,927,932 shares, compared to its average volume of 1,514,369. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a 50 day simple moving average of $266.42 and a 200-day simple moving average of $248.28. The stock has a market cap of $54.66 billion, a P/E ratio of 40.10, a PEG ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.78%. Cencora's dividend payout ratio is currently 31.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at approximately $89,027,442.53. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.